卡培他滨联合肝动脉栓塞化疗治疗原发性肝癌

Efficacy of capecitabine combined with intrahepatic transcatheter arterial chemo embolization in primary hepatic carcinoma

目的 :探讨卡培他滨联合经肝动脉栓塞化疗 (TACE)治疗晚期肝癌的有效性。方法 :6 2例不能手术切除的晚期肝癌患者 (TNM分期Ⅱ～Ⅳ )随机分成两组 :①单纯TACE组 30例 ;②卡培他滨联合TACE组 32例 ,在TACE治疗后第 2天 ,口服给药 14天。全部患者随访两年。比较两组患者的中位生存时间 ,死亡患者平均生存时间、一年生存率、二期手术切除率。结果 :卡培他滨联合TACE治疗组患者的中位生存时间为 14 .5个月 ,一年生存率为 75 .0 % ,二期手术切除率 2 5 .0 % ;而单纯TACE组患者的中位生存时间为 6个月 ,一年生存率为 39.3% ,二期手术切除率 6 .7% ,两组比较有显著差异 (P <0 .0 5 )。结论 :卡培他滨联合TACE治疗晚期原发性肝癌患者的疗效优于单纯TACE。

Purpose:To observe the efficacy of capecitabi ne combined with the transcatheter arterial chemoembolization (TACE) in late-stag e primary hepatic carcinoma.Methods:62 patients of late-stage hepatic carcinoma (TNM: Ⅱ- Ⅳ) were divided into two groups at random:①Simple TACE group: 30 cases;②capec itabine+TACE group:32 cases were given additional oral capecitabine for 14 days the next day after TACE therapy. All the patients were followed for two years.Th e median survival time, the average survival time of dead patients, the 1-year survival rate and the second-stage surgical resection rate of the two groups we re compared. Results:The median survival time of capecitabine+TACE group was 14.5 months, the 1-year survival rate 75%, the second-stage surgical resectio n rate 25%; the TACE group was 6 months,39.3%,6.7% ,respectively. The difference was significant (P<0.05). Conclusions:The therapeutic effect of capecitabine combined wit h TACE is better than that of TACE alone.